FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103017013> ?p ?o ?g. }

• W2103017013 endingPage "1802" @default.
• W2103017013 startingPage "1796" @default.
• W2103017013 abstract "Nitric oxide (NO) is known to have antiatherogenic and anti-inflammatory properties, but its effects on the cytokine-induced nuclear factor-kappa B (NF-kappaB) activation pathway in relation to the regulation of inducible nitric oxide synthase (iNOS) gene in vascular smooth muscle cells (VSMCs) remain elusive. To elucidate the roles of NO in the regulation of cytokine-induced NF-kappaB activation and consequent iNOS gene expression, we studied the effects of NO donors [(+/-)-(E)-ethyl-2-[(E)-hydroxyamino]-5-nitro-3-hexeneamide (NOR3) and sodium nitroprusside] on interleukin (IL)-1beta-induced NF-kappaB activation and IkappaB-alpha degradation and subsequent iNOS expression in rat VSMCs. Northern blot and Western blot analyses demonstrated that NO donors decreased IL-1beta-induced iNOS mRNA and protein expression. Electrophoretic mobility shift assay using synthetic oligonucleotide corresponding to the downstream NF-kappaB site of rat iNOS promoter as a probe showed that NOR3 inhibited IL-1beta-induced NF-kappaB activation and its nuclear translocation, as demonstrated with immunocytochemical study. These effects were independent of guanylate cyclase activation; an inhibitor of soluble guanylate cyclase (1H-oxadiazolo-1,2,4-[4,3-alpha]quinoxaline-1-one) had no effect on NOR3-induced inhibition of NF-kappaB activation or iNOS mRNA expression by IL-1beta, and a cGMP derivative (8-bromo-cGMP) failed to mimic the effects of NO donors. Western blot analysis using anti-IkappaB-alpha and anti-phospho-IkappaB-alpha antibodies revealed that IL-1beta induced a transient degradation of IkappaB-alpha preceded by a rapid appearance of phosphorylated IkappaB-alpha, both of which were completely blocked by NOR3. A proteasome inhibitor (MG115) blocked IL-1beta-induced transient degradation of IkappaB-alpha and stabilized the appearance of phosphorylated IkappaB-alpha stimulated by IL-1beta. NOR3 inhibited the appearance of IL-1beta-induced phosphorylated IkappaB-alpha even in the presence of MG115. Our results indicate that an inhibitory action by NO on cytokine-induced NF-kappaB activation and iNOS gene expression is due to its direct blockade on phosphorylation and subsequent degradation of IkappaB-alpha via the cGMP-independent pathway in rat VSMCs." @default.
• W2103017013 created "2016-06-24" @default.
• W2103017013 creator A5010570123 @default.
• W2103017013 creator A5024762202 @default.
• W2103017013 creator A5041723910 @default.
• W2103017013 creator A5087004159 @default.
• W2103017013 date "1998-11-01" @default.
• W2103017013 modified "2023-09-29" @default.
• W2103017013 title "NO Inhibits Cytokine-Induced iNOS Expression and NF-κB Activation by Interfering With Phosphorylation and Degradation of IκB-α" @default.
• W2103017013 cites W1505685265 @default.
• W2103017013 cites W1562045776 @default.
• W2103017013 cites W1603668575 @default.
• W2103017013 cites W1967154493 @default.
• W2103017013 cites W1977662482 @default.
• W2103017013 cites W1979174681 @default.
• W2103017013 cites W1979520552 @default.
• W2103017013 cites W1980768491 @default.
• W2103017013 cites W1993847641 @default.
• W2103017013 cites W1994303699 @default.
• W2103017013 cites W1997509253 @default.
• W2103017013 cites W2002192155 @default.
• W2103017013 cites W2014797738 @default.
• W2103017013 cites W2015295078 @default.
• W2103017013 cites W2020454682 @default.
• W2103017013 cites W2050283646 @default.
• W2103017013 cites W2055855948 @default.
• W2103017013 cites W2056831005 @default.
• W2103017013 cites W2065257477 @default.
• W2103017013 cites W2080515968 @default.
• W2103017013 cites W2085430726 @default.
• W2103017013 cites W2095019663 @default.
• W2103017013 cites W2101759139 @default.
• W2103017013 cites W2105896882 @default.
• W2103017013 cites W2131868847 @default.
• W2103017013 cites W2135709443 @default.
• W2103017013 cites W2150033965 @default.
• W2103017013 cites W2152098493 @default.
• W2103017013 cites W2158708535 @default.
• W2103017013 cites W2159979956 @default.
• W2103017013 cites W2267941286 @default.
• W2103017013 cites W2470867709 @default.
• W2103017013 cites W4236876345 @default.
• W2103017013 cites W4294216491 @default.
• W2103017013 doi "https://doi.org/10.1161/01.atv.18.11.1796" @default.
• W2103017013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9812920" @default.
• W2103017013 hasPublicationYear "1998" @default.
• W2103017013 type Work @default.
• W2103017013 sameAs 2103017013 @default.
• W2103017013 citedByCount "163" @default.
• W2103017013 countsByYear W21030170132012 @default.
• W2103017013 countsByYear W21030170132013 @default.
• W2103017013 countsByYear W21030170132014 @default.
• W2103017013 countsByYear W21030170132015 @default.
• W2103017013 countsByYear W21030170132016 @default.
• W2103017013 countsByYear W21030170132017 @default.
• W2103017013 countsByYear W21030170132018 @default.
• W2103017013 countsByYear W21030170132019 @default.
• W2103017013 countsByYear W21030170132020 @default.
• W2103017013 countsByYear W21030170132021 @default.
• W2103017013 countsByYear W21030170132022 @default.
• W2103017013 countsByYear W21030170132023 @default.
• W2103017013 crossrefType "journal-article" @default.
• W2103017013 hasAuthorship W2103017013A5010570123 @default.
• W2103017013 hasAuthorship W2103017013A5024762202 @default.
• W2103017013 hasAuthorship W2103017013A5041723910 @default.
• W2103017013 hasAuthorship W2103017013A5087004159 @default.
• W2103017013 hasBestOaLocation W21030170131 @default.
• W2103017013 hasConcept C104317684 @default.
• W2103017013 hasConcept C11960822 @default.
• W2103017013 hasConcept C123298856 @default.
• W2103017013 hasConcept C134018914 @default.
• W2103017013 hasConcept C150194340 @default.
• W2103017013 hasConcept C153911025 @default.
• W2103017013 hasConcept C183978625 @default.
• W2103017013 hasConcept C184235292 @default.
• W2103017013 hasConcept C185592680 @default.
• W2103017013 hasConcept C203014093 @default.
• W2103017013 hasConcept C2776415932 @default.
• W2103017013 hasConcept C2777622882 @default.
• W2103017013 hasConcept C2778690821 @default.
• W2103017013 hasConcept C2779610285 @default.
• W2103017013 hasConcept C519581460 @default.
• W2103017013 hasConcept C55493867 @default.
• W2103017013 hasConcept C62478195 @default.
• W2103017013 hasConcept C86339819 @default.
• W2103017013 hasConcept C86803240 @default.
• W2103017013 hasConceptScore W2103017013C104317684 @default.
• W2103017013 hasConceptScore W2103017013C11960822 @default.
• W2103017013 hasConceptScore W2103017013C123298856 @default.
• W2103017013 hasConceptScore W2103017013C134018914 @default.
• W2103017013 hasConceptScore W2103017013C150194340 @default.
• W2103017013 hasConceptScore W2103017013C153911025 @default.
• W2103017013 hasConceptScore W2103017013C183978625 @default.
• W2103017013 hasConceptScore W2103017013C184235292 @default.
• W2103017013 hasConceptScore W2103017013C185592680 @default.
• W2103017013 hasConceptScore W2103017013C203014093 @default.
• W2103017013 hasConceptScore W2103017013C2776415932 @default.
• W2103017013 hasConceptScore W2103017013C2777622882 @default.

• next